[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracranial-atherosclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracranial-atherosclerosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,51,76,101,127,152,174,198,220,246,272,295,314,342],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100585467","phase-4-pcsk9-inhibitor-with-statin-therapy-for-asymptomatic-intracranial-atherosclerosis-100585467",false,"NCT06902740","PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis","PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis (PISTIAS-2): A Multicenter, Open-label, Blinded-endpoint, Randomized Controlled Trial","PISTIAS-2","Inclusion Criteria:\n\n1. Age ≥18 and ≤80, male or female;\n2. Asymptomatic intracranial artery stenosis (50%-99%) in the internal carotid artery (C6-7 segments), middle cerebral artery (M1 segment), vertebral artery (V4 segment), or basilar artery, confirmed by angiography (MRA, CTA, or DSA);\n3. Atherosclerosis identified as the cause of intracranial artery stenosis by high-resolution magnetic resonance imaging;\n4. No previous ischemic cerebrovascular events (including ischemic stroke or transient ischemic attack).\n5. Baseline low-density lipoprotein cholesterol ≥ 1.8 mmol\u002FL;\n6. Informed consent signed.\n\nExclusion Criteria:\n\n1. Non-atherosclerotic intracranial artery stenosis, including arterial dissection; moya moya disease; systemic vasculitis and primary central nervous system vasculitis; varicella-zoster vasculopathy or other viral vasculopathy; neurosyphilis and other intracranial infections, radiation vasculopathy; fibromuscular dysplasia, sickle cell disease, neurofibromatosis; reversible cerebral vasoconstriction syndrome; postpartum vasculopathy; suspected vasospasm, suspected reperfusion after vessel occlusion.\n2. Upstream tandem extracranial vessel stenosis (≥50%) adjacent to the target intracranial stenotic vessel.\n3. Previous treatment of target intracranial lesion with endovascular intervention or plan to perform endovascular intervention within 6 months, including intracranial stenting, endovascular angioplasty, and thrombectomy.\n4. Any intracranial hemorrhage (parenchymal, subarachnoid, subdural, extradural, intraventricular) within 90 days prior to enrollment.\n5. Presence of intracranial tumors.\n6. Presence of cerebral aneurysms or arteriovenous malformations with indications for interventional therapy.\n7. Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days or planned in the next 6 months after enrollment.\n8. Presence of any of the following unequivocal cardiac sources of embolism: mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, chronic or paroxysmal atrial fibrillation.\n9. New York Heart Association (NYHA) class III or IV, or known left ventricular ejection fraction \\\u003C 30%.\n10. Severe liver dysfunction or severe kidney dysfunction: AST and\u002For ALT \\> 3 times the ULN; creatinine clearance \\\u003C 0.6 mL\u002Fs and\u002For serum creatinine \\> 265 μmol\u002FL (\\>3.0 mg\u002FdL); CK \\>5 times the ULN at screening.\n11. Active bleeding diathesis or coagulopathy (e.g., active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets count \\\u003C 125,000 \u002F uL, hematocrit \\\u003C 30%, Hgb \\\u003C 10 g\u002Fdl, international normalized ratio \\>1.5, bleeding time \\> 1 minute beyond normal value upper limit).\n12. Presence of systemic autoimmune diseases: systemic sclerosis, systemic lupus erythematosus, Sjögren's syndrome, Behçet's disease, mixed connective tissue disease, IgG4-related disease.\n13. Dementia or psychiatric problem that hinder their ability to consistently adhere to an outpatient program. Co-morbid conditions that may limit the life expectancy to less than 3 years.\n14. Relative\u002Fabsolute contraindications to magnetic resonance imaging (MRI) (such as presence of internal metallic objects, claustrophobia, contrast agent allergy, severe renal impairment, epilepsy, hypotension, asthma, and other hypersensitivity respiratory diseases).\n15. Uncontrolled hypertension during the screening period, defined as seated systolic blood pressure (SBP) \\> 180 mmHg or diastolic blood pressure (DBP) \\> 110 mmHg.\n16. Prior use of PCSK9 inhibitor before this recruitment.\n17. Known intolerance or allergy to statin.\n18. Pregnancy, lactation, or planning pregnancy.\n19. Currently participating in another study.","ALL","18 Years","80 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of PCSK9 inhibitor combined with statin therapy compared to statin monotherapy in reversing asymptomatic intracranial atherosclerosis, assessed using high-resolution magnetic resonance imaging of the intracranial vessel walls.",[28,29,30],"Intracranial Atherosclerosis","Intracranial Artery Stenosis","Atherosclerotic Plaque",[28,32,33,34,35,36,37],"intracranial artery stenosis","atherosclerotic plaque","high-resolution magnetic resonance imaging","PCSK9 inhibitor","statin","Recaticimab","RECRUITING","2026-06-10",{"date":41,"type":42},"2026-06-12","ACTUAL",{"date":44,"type":42},"2025-11-07",{"date":46,"type":22},"2028-12-31",{"name":48,"class":49},"Peking Union Medical College Hospital","OTHER",19,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100628961","phase-3-combination-antithrombotic-treatment-for-prevention-of-recurrent-ischemic-stroke-in-intracranial-atherosclerotic-disease-catis--icas-100628961","NCT07468448","Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)","CATIS-ICAS","Inclusion Criteria:\n\n1. Age \\> 40 years\n2. Ischemic stroke or high-risk TIA (motor and\u002F or speech involvement)\n3. Randomization within 30 days of index stroke\n4. Stroke potentially attributable to ICAS 30-99% (or flow gap on time-offlight MRA) of a major intracranial artery (internal carotid artery, middle cerebral artery, anterior cerebral artery, posterior cerebral artery, intracranial vertebral artery, or basilar artery) by MRA or CTA or catheter angiography.\n5. Modified Rankin Scale Score \\\u003C 4 at randomization\n6. Ability to obtain informed consent prior to randomization.\n\nExclusion Criteria:\n\n1. Cardioembolic stroke\n2. Indication for long-term dual antiplatelet or anticoagulant therapy (e.g. venous thromboembolism, coronary stent, mechanical prosthetic valve)\n3. Intracranial arterial stenosis secondary to causes other than atherosclerosis e.g. dissection, moya moya disease\n4. Substantial extracranial carotid artery disease ipsilateral to the qualifying stroke with plans for carotid revascularization\n5. Intended intracranial stenting for the qualifying stroke\n6. Symptomatic hemorrhagic transformation of the index stroke, or neuroradiological class 2 (PH2 type) or symptomatic class 3 on Heidelberg scale prior to randomization\n7. Previous non-traumatic intracerebral hemorrhage, non-aneurysmal subarachnoid hemorrhage (treated aneurysmal subarachnoid hemorrhage will be allowed)\n8. Subdural hematoma within 12 months prior to randomization or traumatic brain hemorrhage within 1 month prior to randomization\n9. Advanced kidney disease at randomization (eGFR \\\u003C15 ml per minute)\n10. Platelet count less than 100,000\u002Fmm3 at enrolment or other bleeding diatheses\n11. Uncontrolled hypertension with BP consistently above 180 mmHg for systolic and 110mmHg for diastolic while on treatment\n12. Known hypersensitivity or contraindication to ASA, clopidogrel or rivaroxaban\n13. Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) or P- glycoprotein (P-gp)\n14. Females of childbearing potential who are not surgically sterile, pregnant, or breast-feeding\n15. Previous randomization to this study\n16. Participating in a study with an investigational drug or medical device that would interfere with the study at the time of randomization (participants that are no longer in an active arm of a study but are being followed may be randomized)\n17. Terminal medical illness with life expectancy less than 1 year","40 Years",{"count":60,"type":22},1172,[62],"PHASE3","CATIS-ICAS is a double-blind, randomized, placebo-controlled (RCT), phase III study seeking to demonstrate that oral rivaroxaban 2.5 mg twice daily plus aspirin daily is superior to clopidogrel 75 mg daily plus aspirin daily for 90 days followed by placebo plus aspirin daily for preventing recurrent stroke in those with ischemic stroke secondary to intracranial atherosclerotic disease (ICAD) of 30-99%, when started within 30 days of index stroke.",[65,28],"Ischemic Stroke","NOT_YET_RECRUITING","2026-03-09",{"date":69,"type":42},"2026-03-12",{"date":71,"type":22},"2026-05-30",{"date":73,"type":22},"2029-12-30",{"name":75,"class":49},"Population Health Research Institute",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100497458","the-efficacy-and-safety-of-intracranial-stent-tonbridge-in-endovascular-treatment-of-symptomatic-intracranial-atherosclerotic-stenosis-100497458","NCT05757505","The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis","The Efficacy and Safety of the Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis: A Prospective, Multicenter, Randomized Controlled, Non-inferiority Trial","Inclusion Criteria:\n\n* Age 18-75;\n* Subjects with symptomatic intracranial atherosclerotic stenosis who do not respond to antiplatelet therapy or have poor compensation of collateral circulation and hypoperfusion in the offending vessel blood supply;\n* The last onset time of TIA is not limited or the last onset of ischemic stroke is more than 2 weeks;\n* The lesion is confirmed to be located in intracranial large arteries, including intracranial segment of the internal carotid artery, middle cerebral artery, intracranial segment of vertebral artery and the basilar artery;\n* Target vessel diameter≥2.0mm and ≤4.5mm, lesion length ≤33mm;\n* Stenosis degree of intracranial arteries≥70% and ≤99% measured by intracranial angiography (WASID method);\n* Intracranial artery stenosis which requiring interventional treatment is a single lesion;\n* Subjects have at least 1 atherosclerotic plaque risk factor including hypertension, diabetes mellitus, hyperlipidemia, hyperhomocysteinemia, coronary heart disease, obesity, and smoking history;\n* mRS≤2 before enrollment;\n* Voluntarily participate in this study and sign the informed consent form, can complete examinations and follow-ups in accordance with the requirements of the protocol during the clinical trial.\n\nExclusion Criteria:\n\n* Intracranial arterial stenosis caused by non-atherosclerotic lesions: such as arterial dissection, moyamoya disease, vasculitis, active arteritis, etc.;\n* Preoperative MRI shows only perforator infarction in the target lesion;\n* Preoperative CT or MRI indicates the presence of post-infarct hemorrhagic transformation in the target vascular, or a history of subarachnoid, subdural, and epidural hemorrhage within 30 days before procedure, or the presence of untreated chronic subdural hematoma (≥5mm);\n* Severe calcification of target vessels; or target vessel tortuosity or other reasons will make experimental device difficult to reach the target lesion position;\n* There is more than 70% stenosis in the distal intracranial large vessels or proximal intracranial and extracranial large vessels of the target vessels, and the presence of unidentified responsible lesions;\n* Subjects have a major surgery within 30 days before procedure or intend to be hospitalized for other procedure within 6 months after procedure;\n* Intracranial tumors or intracranial arteriovenous malformations, or distal and proximal target vessels combined with aneurysms;\n* The target lesion has a history of stent implantation;\n* It is suspected that there is severe allergy or contraindication to aspirin, clopidogrel, heparin, contrast media, nitinol and other drugs and devices related to endovascular therapy;\n* There is an underlying source of cardiac thrombus, such as atrial fibrillation, left ventricular thrombus, myocardial infarction within 30 days;\n* Subjects with an INR \\> 1.5 or the presence of nonmodifiable bleeding factors;\n* Medically uncontrolled severe hypertension (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg);\n* Severe comorbid conditions or unstable conditions, such as severe heart failure, pulmonary failure, or renal failure (serum creatinine \\>3.0 mg\u002FdL (264μmol\u002FL)), severe liver insufficiency (ALT or AST \\>3 times normal), and malignancy;\n* Life expectancy is less than two years;\n* Women who are pregnant or breastfeeding;\n* Subjects unable to complete follow-up due to cognitive impairment, mood disorder, or mental illness;\n* Subjects who are enrolled in other clinical trials of drugs\u002Fdevices and have not yet met the primary endpoint;\n* Other circumstances which investigators do not consider are appropriate for intracranial stent treatment.","75 Years",{"count":85,"type":22},200,[87],"NA","The purpose of this study is to verify the efficacy and safety of the Intracranial Stent (Tonbridge) in endovascular treatment of symptomatic intracranial atherosclerotic stenosis.",[28],"2025-12-30",{"date":92,"type":42},"2026-01-02",{"date":94,"type":42},"2023-05-11",{"date":96,"type":22},"2026-12",{"name":98,"class":99},"Ton-Bridge Medical Tech. Co., Ltd","INDUSTRY",13,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":19,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100614626","phase-2-role-of-glp1-ra-dulaglutide-on-severe-intracranial-atherosclerosis-100614626","NCT07282041","Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis","Role of Glucagon-like Peptide 1 Receptor Agonist (GLP1 RA) Dulaglutide on Cerebral Hemodynamics In Patients With Severe and symptomAtic steNosis of inTracranial Internal Carotid Artery or Middle Cerebral Artery With Impaired Cerebral Vasodilatory Reserve- an Open-label Randomised Clinical Trial (RADIANT)","RADIANT","Inclusion Criteria:\n\n* Adult patients aged 21 - 80 years old inclusive,\n* Able to provide consent,\n* Score 3 or less on the Modified Rankin Score (mRS),\n* Patients with TIA or mild stroke with severe stenosis of intracranial ICA or MCA and impaired CVR within previous 3-months of acute stroke or TIA\n\nExclusion Criteria:\n\n* Chronic kidney disease stage 5 (eGFR\\\u003C15 mL\u002Fmin) or on dialysis,\n* Cancer diagnosed within past 3 years,\n* Currently being planned for coronary or carotid artery revascularization,\n* History of previous pancreatitis,\n* History of medullary thyroid cancer,\n* Atrial fibrillation,\n* Any other condition likely to limit protocol compliance (judged by investigator).\n* For diabetic patients, patients should not be on Sodium-glucose cotransporter 2 (SGLT2) inhibitor or pioglitazone during the duration of the study, unless these drugs can be stopped without affecting participants' medical condition. For those on Dipeptidyl peptidase-4 (DPP IV) inhibitor, this agent will be discontinued if the patient is randomised to the intervention group.\n* Known allergies to Acetazolamide.\n* Women who are pregnant or breastfeeding.","21 Years",{"count":111,"type":22},130,[113,62],"PHASE2","One important mechanism of action of GLP1 RA is the improvement in endothelial function, which may be evaluated by the assessment of cerebral vasodilatory reserve (CVR) in patients with severe ICAD. The investigators believe that GLP1 RA would be beneficial for patients with severe ICAD and lead to an improvement in cerebral vasodilatory reserve (CVR) in patients with severe and recently symptomatic stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA).\n\nIn this open label randomised clinical trial, patients with recently symptomatic and severe stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA) with impaired cerebral vasodilatory reserve (CVR) will be included. CVR will be measured with transcranial Doppler (TCD) breath holding index and acetazolamide-challenged single photon emission computed tomography (SPECT). Patients meeting the eligibility criteria would be randomised to receive best medical therapy (according to the international guidelines and institutional practices) or Dulaglutide subcutaneous injection (0.75mg and titrating to 1.5mg, if indicated) once a week, in addition to the best medical therapy. CVR will be measured again at the completion of 1 year. MRI of the brain will be repeated to evaluate any new ischaemic brain lesions. All patients would be followed up for two years for cerebral ischaemic events.\n\nThe investigators hypothesize that addition of GLP1 RA therapy would lead to a reduction of at least 4 units in CVR on SPECT as compared to best medical therapy.",[28,116],"Stroke, Ischemic","2025-12-16",{"date":119,"type":42},"2025-12-23",{"date":121,"type":42},"2025-12-17",{"date":123,"type":22},"2030-12-01",{"name":125,"class":49},"National University of Singapore",1,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":126},"100552380","intracranial-atherosclerosis-related-large-vessel-occlusion-treated-with-urgent-stenting-icarus-100552380","NCT06472336","IntraCranial Atherosclerosis Related Large-vessel Occlusion Treated With Urgent Stenting (ICARUS)","IntraCranial Atherosclerosis Related Large-vessel Occlusion Treated With Urgent Stenting - a Pragmatic, International, Multicentre, Randomized Trial","Inclusion Criteria:\n\n* A relevant clinical deficit defined as a National Institute of Health Stoke Scale (NIHSS) Score of ≥ 6 points for anterior circulation stroke and a NIHSS Score of ≥ 10 for posterior circulation stroke\n* Anticipated randomization within 24 hours of last seen well (LSW)\n* Occlusion of the Internal Carotid Artery, the M1 segment, the proximal\u002Fdominant M2 segment of the Middle Cerebral Artery, the Basilar Artery or the V4 segment of the Vertebral Artery\n* Absence of recanalization (thrombolysis in myocardial infarction score of 0 or 1) after up to three endovascular treatment passes\n* High probability of underlying intracranial atherosclerotic disease based on the assessment of the treating physician\n* Age ≥ 18 years\n* Occluded artery amendable to stenting by judgement of the treating physician\n* Absence of a large infarct core defined as (posterior circulation) Alberta Stroke Program Early CT Score of 6 or above\n* Informed Consent as documented by signature or fulfilling the criteria for emergency consent procedures\n\nExclusion Criteria:\n\n* Acute intracranial haemorrhage\n* Pre-stroke modified Rankin Scale score of 3 or above\n* Known, severe comorbidities, which will likely prevent improvement or follow-up (cancer, alcohol\u002Fdrug abuse or dementia)\n* Known clotting disease or suspicion of underlying disease which might lead to a hyper coagulant state\n* In-hospital Stroke\n* Known contraindications for anti-platelet therapy\n* Known (serious) sensitivity to radiographic contrast agents, nickel, titanium metals or their alloys\n* Foreseeable difficulties in follow-up due to geographic reasons (e.g., patients living abroad)\n* Evidence of an ongoing pregnancy prior to randomization\n* Radiological confirmed evidence of mass effect or intracranial tumour (except small meningioma)\n* Radiological confirmed evidence of cerebral vasculitis\n* Evidence of vessel recanalization prior to randomisation\n* Participation in another interventional trial which could confound the primary endpoint",{"count":135,"type":22},498,[87],"The goal of this international, multi-center, randomized clinical trial is to compare two treatment options, early intracranial stenting and continued stent-retriever or aspiration based endovascular treatment, for stroke patients with a large vessel occlusion, who experienced failure of recanalisation after initial treatment due to intracranial atherosclerosis.",[139,140,28],"Stroke","Stroke, Acute Ischemic",[142,143],"Endovascular Treatment","Intracranial Stenting","2025-12-09",{"date":121,"type":42},{"date":147,"type":42},"2025-03-31",{"date":149,"type":22},"2027-08",{"name":151,"class":49},"University Hospital, Basel, Switzerland",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":171,"locationsCount":173},"100570998","effect-of-genotype-guided-oral-p2y12-inhibitor-selection-vs-conventional-clopidogrel-therapy-in-symptomatic-icad-100570998","NCT06714526","Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD","Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic Intracranial Atherosclerotic Disease: A Pilot Prospective, Randomized, Open-label, Blinded-endpoint (PROBE) Multi- Centre Study","NUANCE-ICAD","Inclusion Criteria:\n\n* Age ≥ 40 years old, male and female.\n* TIA or ischemic stroke secondary to symptomatic atherosclerotic stenosis of 30- 99% involving the intracranial ICA or MCA or posterior circulation arteries as evidenced by CT or MR angiography.\n* Index TIA or ischemic stroke event occurred within past 30 days.\n* Clinical indication for DAPT for at least 3 months.\n\nExclusion Criteria:\n\n* Any contraindication to DAPT.\n* Any contraindication to use of clopidogrel (Plavix) or ticagrelor (Brilinta), such as pregnancy. A pregnancy test will be performed on all women of child-bearing age prior to enrollment in the study.\n* Indication for chronic anticoagulation based on guideline recommendations or investigator's judgment (e.g., atrial fibrillation, mechanical heart valve, intracardiac clot, dilated cardiomyopathy, ejection fraction \\\u003C30%, etc.).\n* Intracranial arterial occlusion (i.e. 100% stenosis) responsible for the acute brain ischemia.\n* Intracranial arterial stenosis secondary to causes other than atherosclerosis.\n* Extracranial carotid disease with a plan for carotid revascularization.\n* Intraluminal thrombus.\n* Unstable subdural hematoma within 12 months of randomization not amenable to embolization.\n* Previous spontaneous hemorrhagic stroke.\n* Traumatic brain hemorrhage within 1 month of randomization.\n* Living in a nursing home or requiring daily nursing care or assistance with activities of daily living.\n* Intracranial tumor (except meningioma) or any intracranial vascular malformation.\n* Life expectancy less than 6 months.\n* Enrolment in another study that would conflict with the current study.",{"count":161,"type":22},100,[87],"Stroke is an important cause of death, disability, and memory problems in adults. The build-up of plaque in arteries inside the brain is known as \"intracranial atherosclerotic disease\" or \"ICAD\" for short, and can reduce blood flow in the brain. Clopidogrel is a medicine used to prevent strokes because it stops blood from clotting. However, there are some people who do not get as much benefit from Clopidogrel because of differences in their genes; they have a variation in a certain gene and their body is not able to properly process Clopidogrel. Another medication called Ticagrelor can benefit people who have this genetic variation. The study investigators will randomize patients who have had a stroke due to ICAD to receive genetic testing, or standard of care. The standard-of-care group will take Clopidogrel for 90 days. The genetic testing group will complete a genetic test to see if they can properly process Clopidogrel. Depending on the results of the genetic test, patients will either take Clopidogrel or Ticagrelor for 90 days. All patients will have a brain scan at baseline and 90 days to see if they had any new strokes. Patients will also complete tests and questionnaires about function and memory at baseline and 90 days. This study will be one of the first to see if it is feasible and safe to use genetic testing to help choose medications for patients who have had a stroke. This will help the study investigators design a larger study that can test if genetic testing in stroke patients reduces future stroke risk and improves health outcomes.",[28],"2025-11-17",{"date":167,"type":42},"2025-11-20",{"date":169,"type":42},"2025-10-07",{"date":149,"type":22},{"name":172,"class":49},"Sunnybrook Health Sciences Centre",2,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":181,"targetDuration":4,"studyType":182,"phases":4,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":126},"100541923","cognitive-decline-and-underlying-mechanisms-in-symptomatic-intracranial-artery-stenosis-patients-a-cohort-study-100541923","NCT06336174","Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study","Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Atherosclerotic Stenosis Patients: A Multicenter Cohort Study","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Severe stenosis (≥70%-99%) of atherosclerotic internal carotid artery (C6 segment, C7 segment) or middle cerebral artery (M1 segment) confirmed by digital subtraction angiography (DSA) or at least two of the following non-invasive examinations: magnetic resonance angiography (MRA), computed tomography angiography (CTA), or transcranial Doppler (TCD)\n* Transient ischemic attack (TIA) or minor stroke (National Institute of Health Stroke Scale \\[NIHSS\\] score ≤ 4 points)\n* Right-handed and able to cooperate in neuropsychological tests\n* At least 14 days post-onset of cerebral infarction or TIA\n* Signed informed consent\n\nExclusion Criteria:\n\n* Other diseases that affect cognitive function, such as cerebral hemorrhage, •Parkinson's disease, neurosyphilis, dementia, tumors, etc.\n* Right upper limb hemiplegia, aphasia, visual field defects, or visual impairments\n* More than 50% stenosis of the extracranial internal carotid artery, the vertebral artery, or the basilar artery\n* Vasculitis, moyamoya disease, and cardiogenic stroke\n* Previous history of head and neck stent implantation, carotid endarterectomy, aneurysm embolization, or other intracranial surgeries",{"count":161,"type":22},"OBSERVATIONAL","The purpose of this study is to explore the mechanism of cognitive impairment in patients with symptomatic intracranial atherosclerotic stenosis (ICAS), and further plans to explore the impact of different treatment options on cognitive function in symptomatic ICAS patients.",[28,185,186],"Cognitive Impairment","Cerebrovascular Event",[188,185,189],"Symptomatic Intracranial Atherosclerosis Stenosis","Cerebravascular Event","2025-11-14",{"date":165,"type":42},{"date":193,"type":42},"2022-11-01",{"date":195,"type":22},"2026-12-31",{"name":197,"class":49},"Anhui Medical University",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":205,"targetDuration":207,"studyType":182,"phases":4,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":126},"100508225","high-resolution-magnetic-resonance-imaging-of-intracranial-atherosclerotic-plaques-in-ischemic-stroke-100508225","NCT05897645","High-resolution Magnetic Resonance Imaging of Intracranial Atherosclerotic Plaques in Ischemic Stroke","High-resolution Magnetic Resonance Imaging of Intracranial Atherosclerotic Plaques in Ischemic Stroke (HRMRI-ICAS): a Prospective, Multicenter Cohort Study","Inclusion Criteria:\n\n* 1\\. Patient age ≥40 years\n* 2\\. Time of stroke onset: within 2 week\n* 3\\. Baseline NIHSS score ≤16\n* 4\\. Ischemic stroke confirmed by head CT or MRI\n* 5\\. Premorbid mRS ≤1\n* 6\\. The degree of stenosis of extracranial arteries including internal carotid artery, vertebral artery on the lesion side ≤50%\n* 7\\. The culprit plaque or possible culprit plaque with plaque burden of 40% or more found by HRMRI in the proximal part of the middle cerebral artery M1 segment or basilar artery of ipsilateral lesion\n* 8\\. Signed informed consent\n\nExclusion Criteria:\n\n* 1\\. Intracranial hemorrhage found by head CT\n* 2\\. Had a contraindication to MRI,or could not complete required MRI sequences\n* 3\\. Intracranial tumor, arteriovenous malformation, or aneurysm\n* 4\\. Comorbidity with any serious diseases and life expectancy is less than one year\n* 5\\. Pregnancy\n* 6\\. Patients not suitable for this clinical studies considered by researcher",{"count":206,"type":22},2110,"1 Year","Intracranial atherosclerotic disease is the most common cause of ischemic stroke in Asia, also in China. Currently, despite vascular recanalization therapy, statins are one of the main drug choices for treating atherosclerotic plaque. High resolution magnetic resonance imaging (HRMRI) can accurately assess the status of intracranial and extracranial arterial plaque, and has high consistency with histopathology. Thus, HRMRI technology has been widely used to monitor the efficacy of drug treatment for atherosclerotic plaque in clinical trials or practice.\n\nAs a non-invasive technique, HRMRI make it possible to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery in vivo. It can quantitative analysis including components such as lipid-rich necrotic core, fiber cap thickness, intra-plaque hemorrhage, calcification, etc. Therefore, it is crucial for evaluating the etiology of ischemic stroke and developing secondary prevention strategies.\n\nAt present, there is a lack of large-scale and prospective study to evaluate the etiology of ischemic stroke including cryptogenic stroke based on HRMRI. In this context, this study aims to establish a multi center HRMRI database of intracranial arteries among Chinese patients with ischemic stroke.",[139,28,210],"High Resolution Magnetic Resonance Imaging","2025-08-20",{"date":213,"type":42},"2025-08-21",{"date":215,"type":42},"2023-01-19",{"date":217,"type":22},"2026-01-30",{"name":219,"class":49},"General Hospital of Shenyang Military Region",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":228,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":182,"phases":4,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":126},"100563008","icas-screen-based-on-ric-100563008","NCT06610578","ICAS Screen Based on RIC","Intracranial Atherosclerosis Screen Based on Retinal Imaging Characteristic","RICAS","Inclusion Criteria:\n\n1. The age is above 18 years old;\n2. Complete head and neck DSA, CTA, MRA or HR-MRI examination within 2 weeks;\n3. He\u002FShe can cooperate with follow-up fundus examination with free movement;\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Poor quality of fundus images;\n2. With intracranial mass lesions;\n3. With severe heart, liver and kidney diseases;\n4. With pregnancy and lactation.",true,{"count":230,"type":22},2100,"Intracranial atherosclerosis stenosis (ICAS) is a leading cause of ischemic stroke worldwide and increase the global burden of stroke, especially in the Asian population. Compared with the other stroke subtypes, patients with ICAS had more severe stroke, stayed longer in the hospital and higher risk of recurrent ischemic events. Thus, early screening and effective intervention for intracranial atherosclerotic stenosis can improve the level of early warning and prevention of stroke, decrease the incidence and mortality of stroke, which is of vital significance. Although digital subtraction angiography (DSA), computed tomography angiography (CTA) and magnetic resonance angiography (MRA) have a high diagnostic value for ICAS, it is invasive and not available for mass population screening due to expertise, expensive cost, and poor economic performance. Potential screening tools such as transcranial doppler sonography (TCD) are promising but limited by temporal bone window quality and highly depends on operators' experience. Therefore, it is imperative to explore a novel, non-invasive, economic and complementary screening method for identifying the subjects with ICAS in mass populations such as primary health-care institutions and physical examination centers.\n\nThe retina develops from the diencephalon, shares the same embryological origin, anatomic features and physiological properties with brain, including blood supply via the internal carotid artery. A prospective cohort study has confirmed that retinal vascular signs (enhanced arteriolar light reflex) are related to intracranial large artery disease8. Rhee et al' study have also showed that retinal diameter variation is associated with ICAS9. Hence, these findings hint retinal vascular signs may be a biomarker for ICAS. Besides, the traditional vascular risk factors, such as older age, hypertension, diabetes, dyslipidemia, smoking and others, are also tightly associated with ICAS. However, few studies have reported the discrimination performance of retinal vascular signs itself or combining with the traditional vascular risk factors in identifying ICAS. Fundus photography has great advantages including non-invasive, easy to popularize, inexpensive and possess good economic benefits, particularly in the age of artificial intelligence. Artificial intelligence (AI), especially deep learning algorithm has widely applied to accurate varieties of retinal diseases detection and classification such as diabetic retinopathy and glaucoma. Besides, deep learning algorithm was also used to automatic segmentation of retinal arteries or veins, which provides a basis for the subsequent automatic calculation of retinal vascular parameters. In this study, we aim to study on screening for intracranial atherosclerosis and predicting stroke risk based on fundus imaging features.",[28],[234,235,236],"stroke","fundus imaging","intracranial atherosclerosis","2024-10-28",{"date":239,"type":42},"2024-10-31",{"date":241,"type":42},"2024-09-05",{"date":243,"type":22},"2027-09",{"name":245,"class":49},"Xuanwu Hospital, Beijing",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":253,"targetDuration":255,"studyType":182,"phases":4,"briefSummary":256,"conditions":257,"keywords":260,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":4},"100563346","balloon-expandable-des-for-icas-registry-study-bdes-icas-registry-100563346","NCT06614972","Balloon-expandable DES for ICAS Registry Study (BDES-ICAS Registry)","Clinical Outcome of Balloon-Expandable Drug-Eluting Stenting For Patients With Intracranial Atherosclerotic Stenosis: a Prospective, Multicenter, Real-World Registry Study","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. According to clinical and angiographic evidence, symptomatic intracranial arteries stenosis within 3 months include vertebral artery V4 segment or internal carotid artery C2-C7 segment, and the degree of diseased arterial stenosis is between 70%\\~99% (WASID method).\n3. Patients have more than 1 episode of symptoms including stroke or transient ischemia attack (TIA) after intensive medical treatment (including antiplatelet therapy, antihypertensive, hypoglycemic and lipid-lowering treatments).\n4. Patients have at least 1 risk factor for intracranial atherosclerosis, including previous or existing hypertension, hyperlipidemia, diabetes mellitus, smoking, alcohol consumption, obesity, underlying heart disease, family history of atherosclerotic vascular disease, hyperhomocysteinemia and so on.\n5. Baseline mRS score ≤3.\n6. Patient or guardian signs informed consent.\n\nExclusion Criteria:\n\n1. Patients who cannot receive dual antiplatelet therapy due to existing diseases or with server coagulation dysfunction, uncontrolled serious infections, serious systemic diseases, uncontrollable hypertension and other conditions are not suitable for surgery.\n2. Patients with aneurysm that cannot be treated in advance or at the same time or are not suitable for surgery.\n3. Gastrointestinal disease with active bleeding.\n4. Myocardial infarction or massive cerebral infarction within 2 weeks.\n5. Patients with known severe allergies or contraindications to heparin, rapamycin, anesthesia and contrast media.\n6. Life expectancy \\<12 months.\n7. According to the judgement of the investigator, other situations that are not suitable for enrollment.",{"count":254,"type":22},520,"5 Years","To study the clinical outcomes after implantation of balloon-expandable drug-eluting stents in patients with symptomatic intracranial atherosclerotic stenosis in prevention of composite event of any stroke and death within 30 days and ischemic stroke in the territories of the responsible artery from 31 days to 1-year.",[258,28,259],"Atheroscleroses, Cerebral","Ischemia Stroke",[261,262],"Intracranial Atherosclerosis Stroke","Drug-eluting stent","2024-09-23",{"date":265,"type":42},"2024-09-26",{"date":267,"type":22},"2024-09-30",{"date":269,"type":22},"2030-09-30",{"name":271,"class":49},"RenJi Hospital",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":293,"locationsCount":126},"100410696","acoart-intracranial-isr-pilotintracranial-dcb-in-the-treatment-of-intracranial-in-stent-restenosis-100410696","NCT04627870","ACOART Intracranial ISR Pilot:Intracranial DCB in the Treatment of Intracranial In-stent Restenosis","A Prospective, Multi-center, Randomized Controlled Trial to Evaluate the Safety and Feasibility of Intracranial Drug-coated Balloon Catheter in the Treatment of Intracranial In-stent Restenosis","Inclusion Criteria:\n\n* 18 to 80 years of age\n* Confirmed by DSA: in-stent restenosis (ISR) at intracranial segment of internal carotid artery, middle cerebral artery, basilar artery and vertebral artery; ISR is defined as \\>50% stenosis within or immediately adjacent (within 5 mm) of the implanted stent and \\>20% absolute luminal loss\n* presence of ISR associated ischemic stroke or transient ischemic attacks even with medical treatment and strict control of risk factor\n* asymptomatic ISR with severe hypoperfusion in the ISR territories, confirmed by a cerebral blood flow decrease of ≥30% when compared with the perfusion on the contralateral side for anterior circulation lesions or the anterior circulation territory for posterior circulation lesions on CT perfusion, and\u002For by an American Society of Interventional and Therapeutic Neuroradiology\u002FSociety of Interventional Radiology (ASITN\u002FSIR) Collateral Flow Grading System score \\\u003C3 on DSA.\n* the diameter of target vessel is 2.0-4.5mm\n* there is only one intracranial ISR lesion per subject\n* baseline mRS score ≤2\n* Voluntarily participate in this study and sign the informed consent form\n\nExclusion Criteria:\n\n* Patients with stroke within 2 weeks before procedure;\n* any history of brain parenchyma or other intracranial subarachnoid, subdural or extradural hemorrhage in the past 30 days.\n* Those who have received thrombolysis within 24 hours before procedure;\n* Deterioration of neurological function within 24 hours before procedure (defined as NIHSS score increased by ≥ 4 points over the baseline)\n* patients with thrombus in target vessels.\n* in addition to ISR lesions, there are other primary intracranial lesions that need endovascular treatment.\n* Major surgery (including open femoral, aortic or carotid artery surgery) is planned within the past 30 days or within 90 days.\n* patients with renal artery, iliac artery and cardiac coronary artery requiring simultaneous intervention.\n* Combined with intracranial tumors, aneurysms or intracranial arteriovenous malformations.\n* Cardiac stroke or potential cardiogenic thromboembolism, with any of the following cardiogenic embolism causes: chronic or paroxysmal atrial fibrillation, mitral valve stenosis, mechanical valves, endocarditis, intracardiac thrombus or implant, dilated cardiomyopathy, spontaneous acoustic imaging of the left atrium;\n* patients with myocardial infarction within 6 weeks before procedure.\n* those who cannot tolerate general anesthesia due to insufficiency of heart, lung and other important organs.\n* patients with known severe hepatic and renal dysfunction.\n* patients with hemoglobin \\\u003C 100g \u002F L, platelet count \\\u003C 100,000 \u002F mm3, INR \\> 1.5or with uncorrectable factors leading to bleeding.\n* patients who cannot receive dual antiplatelet therapy due to existing diseases or who are tested to be tolerant to dual antiplatelet therapy.\n* Patients with known severe allergies or contraindications to heparin, paclitaxel, contrast agents and other related intravascular treatment drugs\n* current alcohol or drug abuse, uncontrolled severe hypertension (systolic blood pressure \\> 180mmHg or diastolic blood pressure \\> 110mmHg).\n* Life expectancy \\\u003C 1 year.\n* pregnant or lactating women.\n* patients who are unable to complete follow-up due to cognitive, emotional disorders or mental illness.\n* Patients who are participating in other drug\u002Fdevice clinical trials and have not completed all follow-ups required by the programme;\n* According to the judgement of the investigator, other situations that are not suitable for enrollment",{"count":280,"type":22},20,[87],"The purpose of the study is to evaluate the safety and feasibility of drug coated balloon in treatment of intracranial in-stent restenosis.",[28,139],[28,285,286],"In-stent restenosis","drug coated balloon","2024-07-30",{"date":289,"type":42},"2024-08-01",{"date":291,"type":42},"2021-05-26",{"date":90,"type":22},{"name":294,"class":99},"Acotec Scientific Co., Ltd",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":182,"phases":4,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":310,"leadSponsor":312,"locationsCount":173},"100550912","predictors-of-intracranial-atherosclerotic-disease-in-posterior-circulation-a-cohort-study-100550912","NCT06453252","Predictors of Intracranial Atherosclerotic Disease in Posterior Circulation: a Cohort Study","Inclusion Criteria:\n\n1. Adult ≥18 years\n2. Patient with posterior circulation strokes who underwent mechanical thrombectomy.\n\nExclusion Criteria:\n\n1. Patients with anterior circulation stroke.\n2. Patients with intracranial hemorrhage\n3. Patients without baseline radiological data.\n4. Extracranial large vessel atherosclerosis related strokes.",{"count":302,"type":22},150,"Early identification of intracranial atherosclerotic disease (ICAD) may impact the management of patients undergoing mechanical thrombectomy (MT). The aim of the study is to develop and validate a scoring system for pre-thrombectomy diagnosis of ICAD in posterior circulation large vessel\u002Fdistal medium vessel occlusion strokes (LVOs\u002FDMVOs).",[116,28,305],"Posterior Circulation Brain Infarction","2024-07-09",{"date":308,"type":42},"2024-07-10",{"date":289,"type":22},{"date":311,"type":22},"2026-06-30",{"name":313,"class":49},"Sohag University",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":17,"minAge":322,"maxAge":83,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":325,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":126},"100541563","efficacy-of-butylphthalide-on-symptomatic-atherosclerotic-stenosis-in-middle-cerebral-artery-100541563","NCT06331494","Efficacy of Butylphthalide on Symptomatic Atherosclerotic Stenosis in Middle Cerebral Artery","Efficacy of Butylphthalide on Symptomatic Atherosclerotic Stenosis in Middle Cerebral Artery (SICAS): a Prospective, Randomized, Double-blinded, Placebo-controlled, Multiple-center Trial.","SICAS","Inclusion Criteria:\n\n1. Female or male aged 55-75 years;\n2. At least one of the following risk factors of atherosclerosis: hypertension, diabetes, hypercholesterolemia, or smoking;\n3. Symptomatic atherosclerotic stenosis in middle cerebral artery: large artery atherosclerotic cerebral infarction or TIA within 7 days of onset; 70%-99% stenosis of the responsible middle cerebral artery \\[M1\\] confirmed by high-resolution MRI examination (referred to Warfarin-Aspirin Symptomatic Intracranial Disease standard); new-onset infarction confirmed by diffusion weighted imaging (DWI) or TIA symptoms in the territory of the responsible artery supply;\n4. NIHSS ≤ 20;\n5. mRS ≤ 2 at randomization (pre-morbid historical assessment);\n6. Participants understand the purpose of the study and have signed informed consent form.\n\nExclusion Criteria:\n\n1. Presence of intracranial hemorrhage or other pathological brain diseases;\n2. Plan to or have performed intravenous thrombolysis or mechanical thrombectomy therapy;\n3. Unable to undergo MRI examination;\n4. Use Butylphthalide during onset between randomization;\n5. Suspect of cardiac embolism, such as atrial fibrillation, artificial heart valves, endocarditis, etc;\n6. Contraindications for the use of clopidogrel or aspirin;\n7. Known allergy history of celery or butylphthalide;\n8. Severe liver dysfunction (aspartate aminotransferase or alanine transaminase \\> 2 times normal upper limit) or severe renal dysfunction (creatinine value \\> 1.5 times normal upper limit), heart failure, asthma, etc;\n9. History of intracranial hemorrhage, coagulation disorders, systemic bleeding, thrombocytopenia, or other hematological disorders;\n10. Plan to perform other surgical procedures or interventional treatments that may require termination of investigational drug use;\n11. Severe non-cerebrovascular diseases with an expected survival time less than 3 months;\n12. Actively participating in another drug or device trial;\n13. Use any drugs with the same or similar mechanism as Butylphthalide during the follow-up period;\n14. Unsuitable for this trial from the opinion of the investigators.","55 Years",{"count":324,"type":22},140,[87],"Ischemic stroke with high incidence, mortality, disability and recurrence rate, has become the leading threat to the health worldwide. Intracranial atherosclerotic stenosis (ICAS) is commonly associated with ischemic stroke, especially in Chinese residents. Patients with severe ICAS are subject to a very high risk of recurrent stroke events, despite best medical therapy available. Unstable or complex atherosclerotic plaques can lead to plaque ruptures and distal embolisms, thereby increasing the risk of ischemic stroke recurrence. Studies have shown that activation of inflammatory states may play a driving role in the formation and development of atherosclerosis. So far, it remains unclear which are the best treatments for this condition, especially for high-risk patients. Dl-3-n-butylphthalide (NBP) is a Class I novel drug independently developed in China and was officially approved for use in acute ischemic stroke. Preclinical data showed that NBP can act multiple effects of anti-inflammation, antioxidation and anti-apoptosis by suppressing pro-inflammatory factors and upregulating the expression of anti-inflammatory factors. It is still undetermined whether combined therapy with NBP could enhance the curative effect of intracranial atherosclerosis. The primary purpose of this trial is to evaluate the efficacy of butylphthalide in reducing the degree of arterial stenosis and stabilizing plaques in patients with severe symptomatic middle cerebral artery stenosis.",[328,28],"Ischemic Stroke, Acute",[330,331,332,234],"dl-3-n-Butylphthalide","atherosclerotic stenosis","middle cerebral artery","2024-03-19",{"date":335,"type":42},"2024-03-26",{"date":337,"type":22},"2024-03-15",{"date":339,"type":22},"2026-08-31",{"name":341,"class":49},"First Affiliated Hospital, Sun Yat-Sen University",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":350,"targetDuration":352,"studyType":182,"phases":4,"briefSummary":353,"conditions":354,"keywords":358,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":126},"100481520","optical-coherence-tomography-for-intracranial-atherosclerotic-stenosis-100481520","NCT05550077","Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis","Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis: a Prospective Registry Study (OCT-ICAS)","OCT-ICAS","Inclusion Criteria:\n\n* Symptomatic ICAS. Participants with ICAS with a transient ischaemic attack (TIA) or stroke attributable to the territory of the stenotic artery were defined as symptomatic. A TIA was defined as a transient episode of neurological dysfunction (focal weakness or language disturbance, transient monocular blindness, or required assistance in walking) caused by focal brain or retinal ischaemia that lasted for at least 10 minutes but resolved within 24 hours\n* Stenotic degree ≥ 50%, measured by digital subtraction angiography\n* The stenosis must located in at least one major intracranial artery (internal carotid artery, vertebral artery, middle cerebral artery, or basilar artery)\n\nExclusion Criteria:\n\n* Arteriovenous Malformation\n* Aneurysm",{"count":351,"type":22},400,"12 Months","To evaluate the clinical significance of optical coherence tomography (OCT) in interventional treatment of intracranial atherosclerotic stenosis (ICAS).",[28,355,356,357,65],"Optical Coherence Tomography","Plaque, Atherosclerotic","Artery Stenosis",[355,359,360,361],"Intravascular Imaging","Intracranial Atherosclerotic Stenosis","Percutaneous Transluminal Angioplasty and Stenting","2022-09-21",{"date":364,"type":42},"2022-09-23",{"date":366,"type":42},"2020-03-15",{"date":368,"type":22},"2027-12-31",{"name":370,"class":49},"jiaoliqun"]